Concern over a possible AI stock correction is prompting UK investors to be more selective and look at healthcare firms using AI for real medical problems. The article highlights three stocks from its screener, which surfaced 5 more companies not covered. Haleon (LSE:HLN) uses Microsoft data tools and machine learning in product development, marketing and supply chains for brands like Sensodyne and Panadol, with a market value near £33.6b, and its productivity and AI programme has delivered 140 basis points of gross margin improvement. Abingdon Health (AIM:ABDX) makes rapid tests, and its Appdx smartphone reader and AI-led digital services turn them into data-rich diagnostics, with a market value near £39 million.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
artificial intelligencehealthcareUKvaluation
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSFT
• NeutralMicrosoft
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Systems Software |
| Market cap | $3.9T |
| Close on 10/23/2026 | 524.53 |
| Change that session | +0.66% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Haleon And 2 British AI Healthcare Stocks To Watch
The article highlights three UK-listed, AI-driven healthcare stocks, while noting that its screen surfaced five more players that are not covered. Haleon sells over-the-counter consumer health brands and uses Microsoft-powered data tools to guide product development and consumer targeting, with revenue of about £3.8b in North America, £2.6b in APAC and £4.7b in EMEA and Latam, and a market value near £33b. Its productivity and AI programme has already delivered 140 basis points of gross margin improvement. Abingdon Health brings AI into diagnostics through its Appdx smartphone reader, earning about £5 million from contract development and £4.1 million from regulatory services, with a market value near £39 million. AstraZeneca generates about $61.4b from pharmaceuticals, has a market value near £193b, and applies AI within its oncology and drug development work. The article also says AI projects that depend heavily on hardware can stall when financing or public support weakens, while software that helps doctors may scale with fewer physical bottlenecks.
- What Danaher Stock's AI Lab Push Means For Shareholders
Danaher has announced a collaboration with NVIDIA combining its instruments, automation and software with NVIDIA's AI platforms, along with an AI-powered autonomous lab at Abcam for faster custom antibody development. The article links this push to future demand for more automated, data-rich research, but says it does not fundamentally change near-term risk-reward given China trade frictions and volume-based procurement. Analyst models already assume 8.1% annual revenue growth over three years and margin expansion from 15.9% to 19.3%, so the AI initiatives sit within existing expectations. Consensus sees profit rising from US$4.0b today to about US$6.1b by 2029, with the central target of US$236.32 against a US$214.06 share price. The mid case implies a P/E of about 34.1x on 2029 earnings, versus 37.7x today.
- AI Sell - off Exposes the Cost of Financing the Technology Boom
- As AI Labs Burn Cash, the Real Question Is Which Suppliers Get Paid
Microsoft confirmed it is pulling out of a planned UK AI data center being developed by Nscale, because the electricity needed would not be available until the 2030s, while keeping its other agreements with Nscale. The article argues investors should distinguish suppliers paid for hardware, such as Nvidia and Broadcom, from operators like Oracle, CoreWeave and Nebius, which build data centers, rent capacity and must fund infrastructure while waiting for customers to pay. Nvidia has invested in more than 200 companies, while Broadcom's risk lies in customer concentration. AMD is competing with Nvidia through a deal to deploy 6 gigawatts of its GPUs for OpenAI, and it granted OpenAI warrants for up to 160 million AMD shares tied to milestones. Nvidia has also agreed to buy unused CoreWeave computing capacity under certain conditions through 2032.
- Microsoft’s $50 Billion Gamble: Can Microsoft’s Azure Growth Justify Its Exploding AI Budget?
Microsoft reports fiscal first-quarter results on Wednesday, October 28, after the close, and the article says the report will show whether Azure growth can keep pace with its AI spending. In the last quarter of fiscal 2026, revenue reached $90.01 billion, up 17.8%, while Azure grew 43% and passed $100 billion in annual revenue for the first time; commercial RPO rose 84% to $678 billion. Costs rose just as fast: quarterly capex hit $41 billion, and free cash flow fell 23.19% to $19.6 billion. Management guided first-quarter capex above $50 billion including lease reclassification, and expects Azure growth of about 45% in constant currency. The article also highlights Microsoft 365 Copilot passing 30 million paid seats and RPO rising 25% excluding OpenAI.
- Microsoft May Be the Only Hyperscaler to Stay Cash-Flow Positive. What It Means for MSFT Stock
Related markets
Latest news
- If You Invest $1,000 a Year in Morgan Stanley (MS) Stock, How Much Dividend Income Could It Generate Over 20 Years?
Morgan Stanley (MS) currently has a dividend yield of 2.5%, and its dividend has grown at an impressive pace. The article illustrates how investing $1,000 annually over 20 years could generate meaningful dividend income, depending on future dividend growth, stock price growth and whether dividends are reinvested. Assuming the stock grows at an average annual rate of 15%, the investment would be worth about $117,800, and the 20th-year dividend payment would be around $2,950, up from $25 in the first year. The author highlights the power of patience and compounding, and suggests Morgan Stanley may merit a closer look from long-term income-seeking investors.
- Financial Analysis : Fulton Financial ( NASDAQ : FULT ) vs . Central Bancompany ( NASDAQ : CBC )
The article compares Fulton Financial (FULT) and Central Bancompany (CBC), two mid-cap finance companies, across profitability, dividends, earnings, valuation, risk, analyst ratings and institutional ownership. Institutional investors hold 72.0% of Fulton's shares, while company insiders hold 65.9% of Central Bancompany's. Fulton pays an annual dividend of $0.76 per share (3.2% yield) and has raised it for 4 consecutive years, versus $0.48 per share (1.4% yield) for Central Bancompany, with payout ratios of 35.3% and 34.3% of earnings respectively. Fulton has higher revenue and earnings and a lower price-to-earnings ratio, and its consensus price target of $24.75 implies 4.56% potential upside, compared with $35.00 and 0.95% for Central Bancompany. Fulton beats Central Bancompany on 10 of the 16 factors compared. Central Bancompany is a bank holding company headquartered in Jefferson City, Missouri, with $19.2 billion in total assets as of September 30, 2025 and 156 branch locations.
- History Shows 1 Powerful Fact That Makes Me Bullish on VTI
The article argues that long-term investors can look past daily headlines, since the broader U.S. stock market has tended to grow over time, using the Vanguard Morningstar Total Stock Market ETF (VTI) as an example. The fund has been available since May 2001 and delivered average annual returns of 9.44% over 25 years and about 12.6% annualized over the past five years, including through the 2008 financial crisis and the dot-com bear market. VTI holds 3,519 stocks across small-, mid- and large-caps, though it has underperformed the S&P 500 and Nasdaq-100 over the past 10 years. The illustrative math shows a one-time $1,000 investment in 2001 growing to about $9,537, while $300 monthly would have reached about $325,555 and $500 monthly $542,592 after 25 years. The author stresses that past returns do not guarantee future results.
- Expert view: VN-Index has formed a short-term bottom, but this risk needs attention
VN-Index fell sharply in the first two sessions of the 19-23/10 week, at one point dropping to the 1,670-point area, before rebounding on broader buying late in the week to finish up 68.24 points (4%) at 1,774.15. Foreign investors net bought in 2 mid-week sessions but were still net sellers of about VND 969 billion over the five sessions. Mr. Bui Van Huy, CEO of FIDT, believes the market has likely formed a short-term bottom, citing the State Bank's request that banks cut deposit rates for terms of 6 months or longer by at least 0.5% per year and lower lending rates for priority sectors by 1.5-2% per year, along with a P/E excluding Vingroup of below or around 10 times. He cautions, however, that the bottom is not yet sustainable given risks from the Fed, global inflation and domestic inflation (September CPI up more than 5% year on year). He suggests investors consider buying in stages on market pullbacks, limit margin use and watch infrastructure and public investment groups.
- Berkshire Hathaway Stock Rose 10 Days in a Row in October for the First Time Since 2018. Here's What History Says Comes Next.
Class B shares of Berkshire Hathaway closed higher for 10 consecutive sessions from Oct. 1 through Oct. 14, rising from about $498 to $526, before the streak ended on Oct. 15. The stock later topped $547, surpassing the record close of $539.89 set in May 2025. Since 1998, such 10-day winning runs have occurred six other times, and in four of those six cases the shares were higher 12 months later. Under CEO Greg Abel, Berkshire has added to its Alphabet and Delta Air Lines positions and bought back about $4.4 billion of its own stock. The author notes the streak does not guarantee returns over the next 12 months, particularly with shares at a record high, but remains bullish on the company's long-term prospects.
- RBI does not target any price or level for rupee, says Governor Sanjay Malhotra
RBI Governor Sanjay Malhotra said the central bank does not target any price or level for the rupee, but will keep taking necessary measures to curb speculation and excessive volatility and ensure orderly conditions in the forex market. Speaking at the NDTV World Summit 2026 in New Delhi, he said geopolitical tensions, supply chain disruptions, the West Asia conflict and trade uncertainty have made the work of central banks more challenging. He noted that global inflation is elevated and commodity prices are higher, while global growth is lower, at 3.1% this year according to the IMF. He stressed that price stability remains the primary responsibility of central banks, and that inflation in India has risen steadily, largely due to supply-side pressures, to 5.5%. The RBI has raised its policy repo rate by 25 basis points, and its top goal is to rein in inflation while ensuring financial stability.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.